Radiofrequency ablation combined with transarterial chemoembolization in treatment of hepatocellular carcinoma adjacent to the second hepatic hilus
Purpose To explore the efficacy and safety of using radiofrequency ablation (RFA) combined with transarterial chemoembolization (TACE) for treating hepatocellular carcinoma (HCC) adjacent to the second hepatic hilus. Methods Between February 2011 and June 2013, 17 patients with HCC underwent combination therapy of TACE and RFA under DSA and CT guidance at our institution. The 17 patients had a total of 23 hepatic tumors, 17 of which were adjacent to the second hepatic hilus. Results TACE combined with RFA was performed successfully in all 17 patients with no mortalities or major morbidities. During the 1-month follow-up, tumors of 15 patients (88.2%) were completely ablated after one therapy session and 2 patients had detectable tumor residue. During the follow-up time period (range 6–52 months), local tumor progression developed in 1 patient (1/17, 5.9%) and both local tumor progression and new tumors appeared in 1 patient (1/17, 5.9%). Also, new tumors developed in the untreated portions of the liver in 8 patients (8/17, 47.1%). No distant metastasis was found. Of the 17 patients, 6 (35.3%) died due to tumor progression (3/17, 17.6%), liver failure (2/17, 11.8%), or massive hemorrhage of the gastrointestinal tract (1/17, 5.9%). The overall survival rates were 94.1% (16/17), 82.4% (14/17), and 61.8% (11/17) at 12, 18, and 24 months, respectively, and the median survival time was 25 months (95% CI 18–27). Conclusion Treatment using combination of TACE and RFA is an effective and safe therapeutic strategy for treating HCC with tumor(s) adjacent to the second hepatic hilus..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
|---|---|
| Enthalten in: |
Abdominal radiology - 47(2021), 1 vom: 11. Okt., Seite 423-430 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Meng-Li [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Hepatocellular carcinoma |
|---|
| Anmerkungen: |
© The Author(s) 2021 |
|---|
| doi: |
10.1007/s00261-021-03304-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2077840358 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2077840358 | ||
| 003 | DE-627 | ||
| 005 | 20230513222137.0 | ||
| 007 | tu | ||
| 008 | 221220s2021 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00261-021-03304-4 |2 doi | |
| 035 | |a (DE-627)OLC2077840358 | ||
| 035 | |a (DE-He213)s00261-021-03304-4-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Chen, Meng-Li |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Radiofrequency ablation combined with transarterial chemoembolization in treatment of hepatocellular carcinoma adjacent to the second hepatic hilus |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s) 2021 | ||
| 520 | |a Purpose To explore the efficacy and safety of using radiofrequency ablation (RFA) combined with transarterial chemoembolization (TACE) for treating hepatocellular carcinoma (HCC) adjacent to the second hepatic hilus. Methods Between February 2011 and June 2013, 17 patients with HCC underwent combination therapy of TACE and RFA under DSA and CT guidance at our institution. The 17 patients had a total of 23 hepatic tumors, 17 of which were adjacent to the second hepatic hilus. Results TACE combined with RFA was performed successfully in all 17 patients with no mortalities or major morbidities. During the 1-month follow-up, tumors of 15 patients (88.2%) were completely ablated after one therapy session and 2 patients had detectable tumor residue. During the follow-up time period (range 6–52 months), local tumor progression developed in 1 patient (1/17, 5.9%) and both local tumor progression and new tumors appeared in 1 patient (1/17, 5.9%). Also, new tumors developed in the untreated portions of the liver in 8 patients (8/17, 47.1%). No distant metastasis was found. Of the 17 patients, 6 (35.3%) died due to tumor progression (3/17, 17.6%), liver failure (2/17, 11.8%), or massive hemorrhage of the gastrointestinal tract (1/17, 5.9%). The overall survival rates were 94.1% (16/17), 82.4% (14/17), and 61.8% (11/17) at 12, 18, and 24 months, respectively, and the median survival time was 25 months (95% CI 18–27). Conclusion Treatment using combination of TACE and RFA is an effective and safe therapeutic strategy for treating HCC with tumor(s) adjacent to the second hepatic hilus. | ||
| 650 | 4 | |a Radiofrequency ablation (RFA) | |
| 650 | 4 | |a Transarterial chemoembolization (TACE) | |
| 650 | 4 | |a Hepatocellular carcinoma | |
| 650 | 4 | |a Second hepatic hilus | |
| 700 | 1 | |a Li, Hai-Liang |4 aut | |
| 700 | 1 | |a Guo, Chen-Yang |4 aut | |
| 700 | 1 | |a Zhang, Hao |4 aut | |
| 700 | 1 | |a Yuan, Hang |4 aut | |
| 700 | 1 | |a Li, Zhen |4 aut | |
| 700 | 1 | |a Park, Jung-Hoon |4 aut | |
| 700 | 1 | |a Hu, Hong-Tao |0 (orcid)0000-0002-5432-4014 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Abdominal radiology |d Springer US, 2016 |g 47(2021), 1 vom: 11. Okt., Seite 423-430 |w (DE-627)840011903 |w (DE-600)2839786-1 |w (DE-576)451643356 |x 2366-004X |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2021 |g number:1 |g day:11 |g month:10 |g pages:423-430 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s00261-021-03304-4 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 951 | |a AR | ||
| 952 | |d 47 |j 2021 |e 1 |b 11 |c 10 |h 423-430 | ||